ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,352.96
-0.02%
Dow Jones
38,886.17
0.20%
US Dollar vs MXN
17.8861
2.10%
Brent Oil
79.775
1.55%
Bitcoin
70,431.80
-0.90%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Apogee Therapeutics Inc (APGE)

  7. Apogee Therapeutics Inc (APGE) Noticias

APGE

Apogee Therapeutics (APGE)

Apogee Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:APGE
FechaHoraFuenteTítuloSímboloCompañía
30/05/202419:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
30/05/202419:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
28/05/202406:36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:APGEApogee Therapeutics Inc
28/05/202406:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
28/05/202406:30GlobeNewswire Inc.Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MDNASDAQ:APGEApogee Therapeutics Inc
23/05/202406:30GlobeNewswire Inc.Apogee Therapeutics to Participate in Upcoming June Investor ConferencesNASDAQ:APGEApogee Therapeutics Inc
15/05/202415:01GlobeNewswire Inc.Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesNASDAQ:APGEApogee Therapeutics Inc
13/05/202406:26Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APGEApogee Therapeutics Inc
13/05/202406:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APGEApogee Therapeutics Inc
13/05/202406:00GlobeNewswire Inc.Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
06/05/202407:00GlobeNewswire Inc.Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare ConferenceNASDAQ:APGEApogee Therapeutics Inc
25/03/202406:00GlobeNewswire Inc.Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory DiseasesNASDAQ:APGEApogee Therapeutics Inc
12/03/202415:01GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 MillionNASDAQ:APGEApogee Therapeutics Inc
11/03/202405:01Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:APGEApogee Therapeutics Inc
07/03/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APGEApogee Therapeutics Inc
07/03/202417:49GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public OfferingNASDAQ:APGEApogee Therapeutics Inc
07/03/202417:27Edgar (US Regulatory)Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]NASDAQ:APGEApogee Therapeutics Inc
05/03/202415:23GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Proposed Underwritten Public OfferingNASDAQ:APGEApogee Therapeutics Inc
05/03/202415:05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:APGEApogee Therapeutics Inc
05/03/202405:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APGEApogee Therapeutics Inc
05/03/202405:10GlobeNewswire Inc.Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
05/03/202405:00GlobeNewswire Inc.Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of SchNASDAQ:APGEApogee Therapeutics Inc
04/03/202415:01GlobeNewswire Inc.Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024NASDAQ:APGEApogee Therapeutics Inc
02/01/202406:30GlobeNewswire Inc.Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:APGEApogee Therapeutics Inc
13/11/202306:30GlobeNewswire Inc.Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
30/10/202307:00GlobeNewswire Inc.Apogee Therapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:APGEApogee Therapeutics Inc
27/09/202307:42GlobeNewswire Inc.Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) CongressNASDAQ:APGEApogee Therapeutics Inc
14/09/202306:30GlobeNewswire Inc.Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I DayNASDAQ:APGEApogee Therapeutics Inc
29/08/202307:00PR Newswire (US)Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee TherapeuticsNASDAQ:APGEApogee Therapeutics Inc
28/08/202306:30GlobeNewswire Inc.Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:APGE

Su Consulta Reciente

BOV
YBRA4
Ybyra Capital S.A PN
ASX
UTRDC
Ultracharge
UNSW
BTBSETH
BitBase
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados